Publications

Publications

2019

Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. 

Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, Pluim D, Coggins S, Saatci O, Annaratone L, Hm Schellens J, Kim B, Asangani IA, Rasheed SAK, Marchiò C, Sahin O, Ceppi P. Cell Death and Differentiation. 2019 Feb 8. doi: 10.1038/s41418-019-0289-6.

2018

Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma. 

Krumbholz M, Woessmann W, Zierk J, Seniuk D, Ceppi P, Zimmermann M, Singh V, Metzler M, Damm-Welk C. Oncotarget 2018 May 29;9(41):26543-26555.

Polyol pathway links glucose metabolism to the aggressiveness of cancer cells. 

Schwab A, Siddiqui A, Vazakidou ME, Napoli F, Böttcher M, Menchicchi B, Raza U, Saatci Ö, Krebs AM, Ferrazzi F, Rapa I, Dettmer-Wilde K, Waldner MJ, Ekici AB, Rasheed SAK, Mougiakakos D, Oefner PJ, Sahin Ö, Volante M, Greten FR, Brabletz T, Ceppi P. Cancer Research 2018 Apr 1;78:1604-1618.

GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers. 

Rasheed SAK, Leong HS, Lakshmanan M, Raju A, Dadlani D, Chong FT, Rajarethinam R, Skanthakumar T, Tan EY, Hwang JSK, Lim KH, Tan DS, Ceppi P, Wang M, Tergaonkar V, Casey PJ, Iyer G. Oncogene 2018 Mar;37(10):1340-1353.

2017

Thymidylate synthase is functionally associated with ZEB1 and contributes to the epithelial-to-mesenchymal transition of cancer cells. 

Siddiqui A, Vazakidou ME, Schwab A, Napoli F, Fernandez-Molina C, Rapa I, Stemmler MP, Volante M, Brabletz T, Ceppi P. Journal of Pathology. 2017 Jun;242(2):221-233. doi: 10.1002/path.4897.

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. 

Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, Kim J, Zhao JC, Putzbach W, Murmann AE, Chen Z, Chen W, Liu X, Salomon AR, Liu H, Weichselbaum RR, Yu J, Peter ME. Cell Reports. 2017 Mar 7;18(10):2373-2386. doi: 10.1016/j.celrep.2017.02.037

2015

The role of CD95 and CD95 ligand in cancer. 

Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P. Cell Death and Differentiation, 2015 Feb 6.

2014

CD95 and CD95L promote and protect cancer stem cells. 

Ceppi P, Hadji A, Kohlhapp FJ, Pattanayak A, Hau A, Liu X, Liu H, Murmann AE, Peter ME. Nature Communications. Nov2014,5:5238.

Death induced by CD95 or CD95 ligand elimination. 

Hadji A, Ceppi P, Murmann AE, Brockway S, Pattanayak A, Bhinder B, Hau A, De Chant S, Parimi V, Kolesza P, Richards J, Chandel N, Djabalah H, Peter ME. Cell Reports, 2014 Apr 10;7(1):208-22.

2013

Prognostic role of bone sialoprotein in clear cell renal carcinoma. 

Righi L, Bollito E, Ceppi P, Mirabelli D, Tavaglione V, Chiusa L, Porpiglia F,Brunelli M, Martignoni G, Terrone C, Papotti M. Anticancer Research. 2013;33(6):2679-87.

MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. 

Ceppi P, Peter ME. Oncogene. 2014 Jan 16;33(3):269-78.

2012

CD95 is part of a let-7/p53/miR-34 regulatory network. 

Hau A, Ceppi P, Peter ME. PlosOne 2012; 7(11):e49636.

Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation. 

Sprio AE, Di Scipio F, Ceppi P, Salamone P, Di Carlo F, Scagliotti GV, Papotti M, Ceccarelli A, Berta GN. Cancer Chemotherapy and Pharmacology 2012; 69(4):983-9.

Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer. 

Ceppi P, Rapa I, Lo Iacono M, Righi L, Giorcelli J, Pautasso M, Bille A, Ardissone F, Papotti M, Scagliotti GV. International Journal of Cancer 2012, 130:1777-1786.

MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. 

Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, Papotti M, Allgayer H. International Journal of Cancer 2012; 130(9):2044-53.

2011

Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation. 

Lo Iacono M, Monica V, Saviozzi S, Ceppi P, Bracco E, Scagliotti GV. Journal of Translational Medicine. 2011 Jun 30;9:100.

Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. 

Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. Oncogene. 2011 Jun 23;30(25):2888-99.

p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. 

Lo Iacono M, Monica V, Saviozzi S, Ceppi P, Pandiscia S, Billè A, Bracco E, Papotti M and Scagliotti GV. Journal of Thoracic Oncology 2011 Mar;6(3):473-81.

2010

Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. 

Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, Allgayer H. Molecular Cancer Research 2010, 8:1207-1216.

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. 

Righi L, Papotti MG, Ceppi P, Bille` A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, and Selvaggi G. Journal of Clinical Oncology. 2010 Mar 20; 28: 1534-9.

New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS. 

Ceppi P, Papotti MG, Scagliotti G. Advances in Medical Sciences. 2010; 1:22-5.

Emerging role of thymidylate synthase for the pharmacogenomic selection of patients with thoracic cancer. 

Ceppi P, Monica V, Righi L, Papotti M, Scagliotti GV. International Journal of Clinical Pharmacology and Therapeutics. 2010; 7:481-2.

2009

Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. 

Monica V, Scagliotti GV, Ceppi P, Righi L, Cambieri A, Lo Iacono M, Saviozzi S, Volante M, Novello S and Papotti M. Clinical Cancer Research 2009 15:7547-7552.

Chemotherapy Treatment Decisions in Advanced Non- Small Cell Lung Cancer Based on Histology.

Scagliotti G, Ceppi P, Novello N, Papotti M. ASCO Educational Book 2009.

Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. 

Ceppi P, Papotti M, Monica V, Lo Iacono M, Saviozzi S, Pautasso M, Novello S, Mussino S, Bracco E, Volante M, Scagliotti GV. Molecular Cancer Therapeutics 2009 Nov; 8 (11) :3066-74.

Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. 

Volante M, Rosas R, Ceppi P, Rapa I, Cassoni P, Wiedenmann B, Settanni F, Granata R, Papotti M. Journal of Pathology 2009;218(4):458-66.

Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. 

Saviozzi S, Ceppi P, Novello S, Ghio P, Lo Iacono M, Borasio P, Cambieri A, Volante M, Papotti M, Calogero RA, Scagliotti GV. Cancer Research 2009 Apr 15;69:3390-6.

Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. 

Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G, Scagliotti GV, Papotti M. Modern Pathology 2009;22(5):709-17.

Updated clinical information on multitargeted antifolates in lung cancer. 

Scagliotti G, Ceppi P, Capelletto E, Novello S. Clinical Lung Cancer 2009 Volume 10, p35-40.

Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy. 

Ceppi P, Novello S, Cambieri A, Longo M, Monica V, Lo Iacono M, Giaj-Levra M, Saviozzi S, Volante M, Papotti M, Scagliotti GV. Clinical Cancer Research 2009; 15:1039-45.

2008

Prognostic role of osteopontin expression in malignant pleural mesothelioma. 

Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV and Papotti M. American Journal of Clinical Pathology 2008 July 130 (1): 58-64.

Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. 

Ceppi P, Longo M, Volante M, Novello S, Cappia S, Bacillo E, Selvaggi G, Saviozzi S, Calogero R, Papotti M and Scagliotti GV. Journal of Thoracic Oncology, 2008 June 3(6): 583-9.

Human ASH1 expression in prostate cancer with neuroendocrine differentiation. 

Rapa I, Ceppi P, Bollito E, Rosas R, Cappia S, Bacillo E, Porpiglia, Berruti A, Papotti M, Volante M. Modern Pathology. 2008 Jun 21 (6) 700-7.

Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. 

Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV, Papotti M. Clinical Cancer Research. 2008 Feb 15;14(4):1059-64.

2007

Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected non-small cell lung cancer. 

Volante M, Saviozzi S, Rapa I, Ceppi P, Cappia S, Calogero R, Novello S, Borasio P, Papotti M, Scagliotti GV. Cancer. 2007 Sep 15 110 (6):1321-8.

2006

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. 

Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV.  Annals of Oncology. 2006 Dec;17(12):1818-25.

Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. 

Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, Lo Iacono M, Cappia S, Papotti M, Scagliotti GV. Cancer 2006, 107:1589-1596.